Rigel Pharmaceuticals 配当と自社株買い
配当金 基準チェック /06
Rigel Pharmaceuticals配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-0.6%
バイバック利回り
| 総株主利回り | -0.6% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブ更新 • Sep 03
RIGL: Breast Cancer Launch Will Raise Execution Risk For Future Returns
Rigel Pharmaceuticals' analyst fair value estimate has shifted from $38.00 to $43.00 as analysts factor in recent price target increases tied to Veppanu's launch in the U.S., its contribution to a broader long term revenue opportunity, and updated expectations for growth, profitability, and future P/E levels. Analyst Commentary Recent Street research on Rigel Pharmaceuticals highlights growing interest in Veppanu as a new commercial product, but it also shows that some analysts are trying to balance the revenue opportunity with discipline on valuation and execution risk.
ナラティブ更新 • Aug 15
RIGL: Future Returns Will Reflect New Breast Cancer Franchise Expansion
Analysts have raised their price target on Rigel Pharmaceuticals from $57 to $85, citing the addition of Veppanu as a fourth U.S. commercial product and the broader ex-U.S. opportunity from the Kissei partnership as key reasons for the reassessment. Analyst Commentary Analysts covering Rigel Pharmaceuticals are focusing on the addition of Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership when they frame upside and risk to the current valuation.Seeking Alpha • Aug 05
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Summary Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties. Valuation hinges on navigating TAVALISSE's 2032 LOE; downgrading to Hold after the ~50% rally. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 30
RIGL: Veppanu In Licensing And Ex U.S. Breast Cancer Expansion Will Drive Repricing
Rigel Pharmaceuticals' fair value estimate has been revised to $81 from $71 as analysts factor in the Veppanu in-licensing and the broader ex U.S. Rezlidhia opportunity in their updated assumptions. Analyst Commentary Recent research coverage on Rigel Pharmaceuticals has centered on the Veppanu in-licensing and the expanding ex U.S. opportunity for Rezlidhia, with several bullish analysts highlighting these moves as key drivers in their updated views on valuation and execution risk.ナラティブ更新 • Jun 16
RIGL: Breast Cancer Launch Will Drive Future Upside Potential
Analysts nudged their price target on Rigel Pharmaceuticals higher to $81 from $69, citing the Veppanu in-licensing agreement and the expanding Rezlidhia partnership footprint as key drivers behind their updated view. Analyst Commentary Recent research on Rigel Pharmaceuticals has centered on two main themes: the expanding reach of Rezlidhia outside the U.S. and the Veppanu licensing deal with Pfizer and Arvinas.ナラティブ更新 • Jun 02
RIGL: Breast Cancer Launch And Ex U S Expansion Will Shape Future Upside
Analysts raised their price targets on Rigel Pharmaceuticals, including Citi's increase from $69 to $81 per share. They cited the Veppanu in-licensing and the Rezlidhia ex U.S. NDA as key reasons for their revised views.ナラティブ更新 • May 13
RIGL: Execution On Breast Cancer Franchise Will Shape Future Upside Potential
Analysts trimmed their price target on Rigel Pharmaceuticals by $2 as they factor in updated views on growth, profitability and future P/E multiples, even while recent commentary suggests Pfizer's handoff of Veppanu to Rigel could support the company's long term positioning. Analyst Commentary Recent Street views on Rigel Pharmaceuticals highlight a mix of longer term opportunity around Veppanu and nearer term caution on execution, growth visibility and valuation.分析記事 • May 12
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position
The latest earnings release from Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) disappointed investors. We did some...ナラティブ更新 • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.ナラティブ更新 • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.ナラティブ更新 • Mar 31
RIGL: Higher Future P/E Assumptions Will Support Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts describe the latest US$2 increase in the price target as a reflection of refreshed assumptions on discount rates, revenue potential, and profitability for Rigel Pharmaceuticals.ナラティブ更新 • Mar 17
RIGL: Margin Improvement Execution Will Shape Future Upside Potential
Analysts have increased their price target on Rigel Pharmaceuticals by $2, reflecting updated views on slightly adjusted growth assumptions, a modestly higher discount rate, and expectations for improved profit margins alongside a lower future P/E. Analyst Commentary Recent research around Rigel Pharmaceuticals points to a mixed setup, where the updated price target and refined assumptions are paired with a clear emphasis on execution and margin discipline.ナラティブ更新 • Mar 03
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.ナラティブ更新 • Feb 17
RIGL: Updated Earnings Outlook And P/E Assumptions Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals by $2 to $71, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has leaned positive, with bullish analysts using the higher fair value estimate and updated P/E assumptions to support their case for upside potential.ナラティブ更新 • Feb 03
RIGL: Higher 2025 Sales Guidance And Execution Will Shape Future Upside And Risks
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals from $23 to $38 per share, pointing to raised Street price targets, stronger recent product sales versus expectations, higher 2025 sales guidance in the US$225m to US$230m range, solid commercial execution, improving profitability assumptions and a higher future P/E multiple. Analyst Commentary Recent Street research has highlighted Rigel Pharmaceuticals' stronger product sales versus expectations and higher 2025 net product sales guidance in the US$225m to US$230m range, alongside raised price targets in some cases.ナラティブ更新 • Jan 19
RIGL: Future Returns Will Reflect Raised 2025 Sales Guidance And Positive Cash Flow
Analysts have nudged their fair value estimate for Rigel Pharmaceuticals slightly higher to US$51.60 from US$51.20, citing recent price target increases and upgrades that highlight strong commercial execution, improved 2025 net product sales guidance to US$225m to US$230m, positive cash flow, and potential for further business development. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has focused on how the company is executing against its guidance and what that might mean for valuation.分析記事 • Jan 08
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブ更新 • Jan 05
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts nudged their fair value estimate for Rigel Pharmaceuticals higher from US$49.60 to US$51.20, citing stronger Q3 product sales, increased 2025 net product sales guidance to US$225m to US$230m, improved profit margin assumptions and a slightly lower future P/E multiple following recent research upgrades. Analyst Commentary Recent research updates point to a constructive shift in sentiment around Rigel Pharmaceuticals, driven by Q3 performance and revised 2025 guidance.ナラティブ更新 • Dec 20
RIGL Q3 Execution And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by about $2 to reflect stronger expected revenue growth, higher profit margins, and improved commercial execution highlighted by recent Street research. Analyst Commentary Bullish analysts have highlighted Rigel Pharmaceuticals as a compelling growth story in the mid-cap biotech space, pointing to recent guidance increases and stronger than expected product sales as key drivers of renewed enthusiasm.ナラティブ更新 • Dec 06
RIGL: Future Results Will Reflect Sustained Execution Amid Emerging Commercial And Pipeline Milestones
Analysts have raised their price target for Rigel Pharmaceuticals by $3, increasing it to $49.60 from $46.60. This change reflects increased confidence in stronger revenue growth, higher profit margins and solid commercial execution highlighted in recent research.分析記事 • Nov 27
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...ナラティブ更新 • Nov 22
RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance
Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.分析記事 • Nov 12
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...ナラティブ更新 • Nov 07
RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast
Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.分析記事 • Sep 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Key Insights The projected fair value for Rigel Pharmaceuticals is US$39.23 based on 2 Stage Free Cash Flow to Equity...分析記事 • Sep 25
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 26% in the last month, reversing a fair...分析記事 • Sep 03
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブ更新 • Aug 07
Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).分析記事 • Aug 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:RIGL 1 Year Share Price vs Fair Value Explore Rigel Pharmaceuticals's Fair Values from the Community and...分析記事 • May 15
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Rigel Pharmaceuticals will host its Annual General Meeting on 22nd of May Total pay for CEO Raul Rodriguez...分析記事 • May 09
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) defied analyst predictions to release its first-quarter results, which were...分析記事 • Apr 02
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 11
Rigel Looks Interesting, But Let's Wait For A Lower Price
Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-risk myelodysplastic syndromes, with good safety and efficacy profiles. Rigel has a strong financial position with a market cap of $366mn, $77mn cash, and projected 2025 revenue of $200-$210 million. Despite positive financials and promising drug data, since RIGL is trading at a 52-week high, I recommend waiting for a lower price to buy. Read the full article on Seeking Alpha決済の安定と成長
配当データの取得
安定した配当: RIGLの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: RIGLの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Rigel Pharmaceuticals 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (RIGL) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.1% |
| 業界平均 (Biotechs) | 2.2% |
| アナリスト予想 (RIGL) (最長3年) | 0% |
注目すべき配当: RIGLは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: RIGLは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: RIGLの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: RIGLが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/11 17:49 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Rigel Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20
| アナリスト | 機関 |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |